PLC Systems Launches New Web Site To Focus on Its New Investigational System, RenalGuard(TM)
2007年10月23日 - 9:15PM
PRニュース・ワイアー (英語)
FRANKLIN, Mass., Oct. 23 /PRNewswire-FirstCall/ -- PLC Systems Inc.
(AMEX:PLC), a company focused on innovative cardiac and vascular
medical device-based technologies, announced today that it has
launched a new corporate web site (http://www.plcmed.com/). In
addition to offering fresh corporate information, the new website
is designed to provide educational resources related to
Contrast-Induced Nephropathy (CIN) and TransMyocardial
Revascularization (TMR), two areas that the company's proprietary
technology targets. It includes updates on the company's progress
with its investigational system, RenalGuard(TM), that targets CIN,
and other information geared towards medical professionals,
investors, and partners into a single-facing website. To that end,
the new website incorporates a variety of educational materials,
information on both RenalGuard and the CO2 Heart Laser 2(TM), which
enables TMR procedures, and investor resources. With the addition
of RenalGuard to its product portfolio, PLC required a more
comprehensive online presence. The new site provides expanded
information on RenalGuard Therapy and RenalGuard System,
comprehensive overviews related to CIN, a form of Acute Renal
Failure, professional and patient information related to TMR and
the benefits of the CO2 Heart Laser 2, investor relations
materials, and updates on the company. It features a new graphic
approach for the company, more reflective of its market and
audiences. "Our new web site gives us the ability to provide a
wider range of information on our products and their related
disease states to clinicians, our investors and to the general
public," stated Mark R. Tauscher, President and CEO of PLC Systems
Inc. "We see this expansion of informational and educational
resources as a vital way to maintain updated communications with
all of our constituents and ensure that knowledge and awareness of
PLC Systems is current and accurate, in an appealing and
easy-to-navigate graphical setting." RenalGuard(TM) is an
investigational system and therapy that targets patients with
compromised renal function who may be at risk for CIN, when
undergoing cardiovascular imaging procedures. RenalGuard
Therapy(TM) is based on initial pre-clinical study data that
suggests that initiating and maintaining high urine output during
imaging procedures allows the body to rapidly eliminate toxins in
contrast media, reducing their harmful effects. The RenalGuard
System(TM) is a fully-automated, real-time matched fluid
replacement device intended for the at-risk segment of the millions
of interventional cardiology and radiology patients undergoing
these procedures. About PLC Systems Inc. PLC Systems Inc. is a
medical technology company specializing in innovative technologies
for the cardiac and vascular markets. Headquartered in Franklin,
Mass., PLC pioneered the CO2 Heart Laser System, which cardiac
surgeons use to perform CO2 transmyocardial revascularization (TMR)
to alleviate symptoms of severe angina. CO2 TMR offers a treatment
option for angina patients who suffer from severe coronary artery
disease. The CO2 Heart Laser is the world's first TMR angina relief
device cleared for commercial distribution by both the U.S. Food
and Drug Administration and Japanese Ministry of Health, Labor and
Welfare, and to obtain a CE Mark for European distribution. The
company is currently conducting a pilot clinical safety study of
its RenalGuard Therapy and RenalGuard System. RenalGuard Therapy is
designed to reduce the toxic effects that contrast media can have
on the kidneys. This therapy is based on the theory that creating
and maintaining a high urine output is beneficial to patients
undergoing imaging procedures where contrast agents are used. The
real-time measurement and matched fluid replacement design of the
RenalGuard System is intended to ensure that a high urine flow is
maintained before, during and after these procedures. This should
allow the body to rapidly eliminate contrast, reducing its toxic
effects. The RenalGuard System with its matched fluid replacement
capability is intended to minimize the risk of over- or
under-hydration. Additional company information can be found at
http://www.plcmed.com/. This press release contains
"forward-looking" statements. For this purpose, any statements
contained in this press release that relate to prospective events
or developments are deemed to be forward-looking statements. Words
such as "believes," "anticipates," "plans," "estimates," "expects,"
"will" and similar expressions are intended to identify forward-
looking statements. Our statements of our objectives are also
forward-looking statements. While we may elect to update
forward-looking statements in the future, we specifically disclaim
any obligation to do so, even if our estimates change, and you
should not rely on these forward-looking statements as representing
our views as of any date subsequent to the date of this press
release. Actual results could differ materially from those
indicated by such forward-looking statements as a result of a
variety of important factors, including we may not receive
necessary regulatory approvals to market our RenalGuard product,
the clinical trials for that product may not be successful, the
RenalGuard product may not be commercially accepted, operational
changes, competitive developments may affect the market for our
products, regulatory approval requirements may affect the market
for our products, and additional risk factors described in our
Quarterly Report on Form 10-Q for the three months ended June 30,
2007, and our other reports filed with the Securities and Exchange
Commission. PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser,
RenalGuard, RenalGuard System and RenalGuard Therapy are trademarks
of PLC Systems Inc. Contact: Mary T. Conway Conway Communications
617-244-9682 DATASOURCE: PLC Systems Inc. CONTACT: Mary T. Conway
of Conway Communications, +1-617-244-9682, Web site:
http://www.plcmed.com/
Copyright
P L C Systems (AMEX:PLC)
過去 株価チャート
から 11 2024 まで 12 2024
P L C Systems (AMEX:PLC)
過去 株価チャート
から 12 2023 まで 12 2024